Target Details
| UniProt AC | P42345 |
|---|---|
| Gene Symbol | MTOR |
| Protein Name | Serine/threonine-protein kinase mTOR |
| Organism | Homo sapiens |
| Entry Name | |
| Organism Category | Human |
| Pfam Domains | PF02259 (FAT) PF02260 (FATC) PF08771 (FRB_dom) PF23593 (HEAT_ATR) PF11865 (mTOR_dom) PF00454 (PI3_PI4_kinase) |
Summary
- Multi-target molecules 2,517
- Clinical molecules 193
- Avg pChEMBL 7.75
KEGG Pathways (53)
- AMPK signaling pathway
- Acute myeloid leukemia
- Adipocytokine signaling pathway
- Alzheimer disease
- Amyotrophic lateral sclerosis
- Apelin signaling pathway
- Autophagy - animal
- Autophagy - other
- Breast cancer
- Cellular senescence
- Central carbon metabolism in cancer
- Chemical carcinogenesis - receptor activation
- Choline metabolism in cancer
- Colorectal cancer
- Diabetic cardiomyopathy
- EGFR tyrosine kinase inhibitor resistance
- Endocrine resistance
- ErbB signaling pathway
- Gastric cancer
- Glioma
- Growth hormone synthesis, secretion and action
- HIF-1 signaling pathway
- Hepatocellular carcinoma
- Herpes simplex virus 1 infection
- Human cytomegalovirus infection
- Human immunodeficiency virus 1 infection
- Human papillomavirus infection
- Huntington disease
- Insulin resistance
- Insulin signaling pathway
- Integrin signaling
- JAK-STAT signaling pathway
- Kaposi sarcoma-associated herpesvirus infection
- Longevity regulating pathway
- Longevity regulating pathway - multiple species
- Lysosome biogenesis
- MicroRNAs in cancer
- Neutrophil extracellular trap formation
- PD-L1 expression and PD-1 checkpoint pathway in cancer
- PI3K-Akt signaling pathway
- Pancreatic cancer
- Pathways in cancer
- Pathways of neurodegeneration - multiple diseases
- Phospholipase D signaling pathway
- Prostate cancer
- Proteoglycans in cancer
- Shigellosis
- Spinocerebellar ataxia
- Th17 cell differentiation
- Thermogenesis
- Thyroid hormone signaling pathway
- Type II diabetes mellitus
- mTOR signaling pathway
Associated Diseases (2)
Active Molecules (2,517)
| InChIKey | pChEMBL | Type | Targets | Clinical | |
|---|---|---|---|---|---|
KPJPCGHPNIPOEU
|
9.0 | pIC50 | 2 | Yes | |
KUWGSNAXZXLPHP
|
9.0 | IC50 | 2 | — | |
LCGRAUSKPSGLOT
|
9.0 | pIC50 | 2 | Yes | |
LHSZSFCGMVMSQY
|
9.0 | IC50 | 2 | — | |
LOQIPIKMODPFHY
|
9.0 | IC50 | 3 | — | |
LSPYTXAQSKEIJE
|
9.0 | IC50 | 2 | — | |
LXFGQYHRDFXPKF
|
9.0 | IC50 | 2 | — | |
NLNIZBXJXWGGBP
|
9.0 | IC50 | 2 | — | |
OQNJPLOGLRYYQL
|
9.0 | IC50 | 2 | — | |
RJQLIBITTSLUFF
|
9.0 | IC50 | 2 | — | |
SJOBNHMHLYWXLM
|
9.0 | IC50 | 2 | — | |
SLESJLZOADSRKF
|
9.0 | IC50 | 3 | — | |
SOKZAWDIWZGGPU
|
9.0 | IC50 | 2 | — | |
SSAOLUQEPNDEQO
|
9.0 | IC50 | 2 | — | |
SVYIKFBOHAXKMT
|
9.0 | IC50 | 2 | — | |
VKNPVEGBOPKZQJ
|
9.0 | IC50 | 2 | — | |
VPYQLUBFHONSEW
|
9.0 | IC50 | 2 | — | |
VTFLALQGBLPAOI
|
9.0 | IC50 | 2 | — | |
VXTMTTWBWRDTGW
|
9.0 | pIC50 | 2 | Yes | |
WCAZAKPQNWSACH
|
9.0 | IC50 | 2 | — | |
WOMZEPGGVURQNJ
|
9.0 | IC50 | 2 | — | |
WTSKLBVBUJRZSO
|
9.0 | IC50 | 2 | — | |
WXXQJPCZRLPSPS
|
9.0 | IC50 | 3 | — | |
XDWRYVRDKJOART
|
9.0 | IC50 | 3 | — | |
YBKJDNVXZBTIRO
|
9.0 | pIC50 | 3 | Yes | |
YPCCVXJXZXZPEQ
|
9.0 | IC50 | 2 | — | |
ZFKUIXUALOAFLP
|
9.0 | IC50 | 3 | — | |
AVOLABBAFBXDDY
|
9.0 | IC50 | 2 | — | |
CXNJMEKHRWATCZ
|
9.0 | IC50 | 3 | — | |
KZMQGBUVYQNFQQ
|
9.0 | IC50 | 2 | — | |
WIDRBUSEFGYJCE
|
9.0 | Ki | 2 | — | |
VNHKSWWLDVWBFT
|
9.0 | Ki | 2 | — | |
AFILYMFIVVCTKT
|
9.0 | pIC50 | 2 | Yes | |
AQYTWWQAZAOONP
|
9.0 | IC50 | 5 | — | |
GQCPOWLHVMDLGD
|
9.0 | IC50 | 3 | — | |
HEPQUAOIJVKVMV
|
9.0 | IC50 | 2 | — | |
JVGONGAUWGLLLU
|
9.0 | IC50 | 2 | — | |
MROYPAGLZHRREL
|
9.0 | IC50 | 2 | — | |
PDNXSGBKBLMGHI
|
9.0 | IC50 | 3 | — | |
PRNOUMSQOOBTIW
|
9.0 | IC50 | 3 | — | |
SWBBUJJFFCMXKV
|
9.0 | IC50 | 2 | — | |
UYODWJJWEBPJCV
|
9.0 | IC50 | 2 | — | |
VGMKYCYGESGMRO
|
9.0 | IC50 | 3 | — | |
XHNJXQFICQUYRG
|
9.0 | IC50 | 2 | — | |
XYPJLNXIABOGTO
|
9.0 | IC50 | 2 | — | |
CJZBLYPPXFPDIA
|
8.9 | Ki | 2 | — | |
SZZVBXCMBWROMR
|
8.9 | IC50 | 2 | — | |
VVVPWJKRDCCYGB
|
8.9 | IC50 | 2 | — | |
GPMYHUFPZPEWRL
|
8.9 | IC50 | 2 | — | |
VIZDWFMDXKHPJD
|
8.9 | IC50 | 2 | — |